Nuvation Bio Inc. (NUVB)

USD 2.1

(5.81%)

Long Term Debt Summary of Nuvation Bio Inc.

  • Nuvation Bio Inc.'s latest annual long term debt in 2023 was 2.03 Million USD , down -33.37% from previous year.
  • Nuvation Bio Inc.'s latest quarterly long term debt in 2024 Q2 was 274.93 Million USD , down 0.0% from previous quarter.
  • Nuvation Bio Inc. reported annual long term debt of 3.05 Million USD in 2022, up 39.32% from previous year.
  • Nuvation Bio Inc. reported annual long term debt of 2.19 Million USD in 2021, down 0.0% from previous year.
  • Nuvation Bio Inc. reported quarterly long term debt of 1.5 Million USD for 2024 Q1, down 0.0% from previous quarter.
  • Nuvation Bio Inc. reported quarterly long term debt of 2.03 Million USD for 2023 FY, down -33.37% from previous quarter.

Annual Long Term Debt Chart of Nuvation Bio Inc. (2023 - 2018)

Historical Annual Long Term Debt of Nuvation Bio Inc. (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 2.03 Million USD -33.37%
2022 3.05 Million USD 39.32%
2021 2.19 Million USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%

Peer Long Term Debt Comparison of Nuvation Bio Inc.

Name Long Term Debt Long Term Debt Difference
ADC Therapeutics SA 112.73 Million USD 98.195%
Alto Neuroscience, Inc. 151.33 Million USD 98.655%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 27.56 Million USD 92.619%
Ginkgo Bioworks Holdings, Inc. 221.83 Million USD 99.083%
Nuvation Bio Inc. 2.03 Million USD 0.0%
Arcus Biosciences, Inc. 110 Million USD 98.15%
Zymeworks Inc. 22.46 Million USD 90.94%